Study of MEDI-547 to Evaluate the Safety, Tolerability, and Biologic Activity of IV Administration in Subjects With Relapsed or Refractory Solid Tumors

Summary

To determine the safety, tolerability, and the highest dose of this drug given once every 3 weeks or once every week, (per 21 day cycle) in adult subjects with relapsed or refractory solid tumors.

Timeline

Start

2009-08

Primary completion

2010-02

Completion

2010-06

Outcome

Outcome not reported

Stopped (Business): “MI-CP177 study closed per sponsor decision.”

Drugs

Indications